Deciphera Pharmaceuticals Secures $15,000,000 Series B Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=6d9d6d91-dcb3-4b95-9d51-d24a2b44d0c4 - Date
1/5/2016 - Company Name
Deciphera Pharmaceuticals - Mailing Address
1601 Trapelo Road Waltham, MA 02451 USA - Company Description
Deciphera Pharmaceuticals, LLC was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce best-in-class small molecule switch inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform. - Website
http://www.deciphera.com - Transaction Type
Venture Equity - Transaction Amount
$15,000,000 - Transaction Round
Series B - Proceeds Purposes
SV Life Sciences’ investment will contribute to rapid progression of Deciphera’s lead tumor-targeting clinical programs, including Altiratinib and DCC-2618, as well as its immuno-targeted therapies such as DCC-3014 and Rebastanib, offering the potential to provide patients with innovative new therapeutic options while building a strong oncology-focused biotechnology company. - M&A Terms
- Venture Investor
SV Life Sciences
